or LPT. The application of LPT once daily for 7 consecutive days reduced the concentration of bacteria in the lungs approximately 30-fold compared with sham therapy. In a follow-up study, Creasy et al 20 found that 3 applications once daily for 3 consecutive days of either thoracic or abdominal LPT were able to significantly (P<.05) reduce the numbers of pulmonary S pneumoniae colony-forming units (CFU) compared with control or sham therapy. These results suggest that LPT may protect against bacterial pneumonia by inhibiting bacterial growth in the lung; however, the mechanism responsible for this clearance is still under investigation.
To our knowledge, no study has been published to show that lymphatic treatments, such as LPT, affect drug efficacy. In the current study, we hypothesized that the combination of antibiotics and LPT would reduce the concentration of bacteria in the lungs of rats infected with S pneumoniae. Antibiotics are generally used to manage bacterial pneumonia and other infectious diseases; therefore, it is important to identify how complementary therapies, such as LPT, affect antibiotic efficacy.
Methods

Animals
The present study was approved by the Institutional Animal Care and Use Committee and conducted in accordance with the Guide for the Care and Use of Laboratory Animals. 21 Male inbred Fischer 344 rats, free of clinically evident signs of disease and weighing between 200 to 300 g, were used. The rats had indwelling jugular vein catheters, which remained in place for the duration of the study.
Infection
Anesthesia was delivered (30 mg/kg ketamine and 5 mg/ kg xylazine), and the rats were intranasally inoculated with 5×10 7 S pneumoniae (ATCC 6301) CFU in 100 µL of phosphate-buffered saline (PBS). After infection, the rats were held vertically for a few seconds to allow for aspiration of the fluid. No substantial weight loss or any therapies that shorten hospitalization or allow outpatient management should be exploited.
Lymphatic pump treatment (LPT) comprises osteopathic manipulative medicine techniques that target the musculoskeletal system and enhance the flow of lymph through the lymphatic system. 4, 5 Clinically, LPT is reported to increase vaccine-specific antibodies, 6, 7 reduce the need for intravenous antibiotics, 8, 9 protect against lower respiratory tract disease, [8] [9] [10] and shorten the duration of hospital stay in elderly patients with pneumonia. 9 To our knowledge, no reports have been published measuring the effects of LPT on the lymphatic system in humans, but animal studies have demonstrated that LPT yields significant (P<.05) increases in lymph flow and in the lymphatic concentration of leukocytes.
11-18
In these studies, LPT did not preferentially mobilize any specific immune cell population, but it significantly (P<.05) increased thoracic duct lymph flow and total leukocyte concentrations, resulting in an approximately 10-fold increase in the lymphatic flux. 12 Lymphatic pump treatment also significantly (P<.05) enhanced the lymphatic flux of inflammatory cytokines, chemokines, and reactive oxygen and nitrogen species in both thoracic and mesenteric lymph, 17, 18 and it enhanced the uptake of protein from the tissue's interstitial space. 19 Collectively, these studies suggest that LPT can enhance the lymphatic and immune system responses, which may accelerate the clearance of pneumococcal bacteria.
A study published in 2010 15 used a rat model to investigate the effect of LPT on lymphatic function.
Rats received LPT in a manner similar to that reported previously, 19 and lymph was collected from the cisterna chyli. Four minutes of LPT caused a statistically significant increase in lymph flow and leukocyte concentrations. These results were consistent with findings in dogs [11] [12] [13] 16 and demonstrated the enhanced lymph flow and the lymphatic release of immune cells induced by LPT in a smaller animal.
In a later study, 14 rats were infected intranasally with
Streptococcus pneumoniae and received sham therapy resuspended in sterile PBS. At 24, 48, and 72 hours after infection, rats received no manual therapy (control),
sham therapy, or LPT followed by subcutaneous injection of 40 mg/kg of levofloxacin or sterile PBS.
Interventions
Abdominal LPT was applied to rats as previously described. 14, 15, 20 Briefly, anesthetized (10 mg/kg propofol) rats were kept in a right lateral recumbent position. To 
Statistical Analysis
A power analysis performed using the SD from our preliminary studies confirmed that 8 rats per group were sufficient for detecting differences between the means of the experiments, with a power of 0.90. Data on CFU other clinical signs of disease were observed in the animals during the study (data not shown). Therefore, "disease free" was defined as an absence of S pneumoniae in lung homogenates.
Leukocyte Enumeration
Blood samples were collected by means of cardiac puncture and drawn into EDTA-coated vacutainer blood test tubes. Total leukocytes and a differential leukocyte count were enumerated using an automatic hematology analyzer.
Bacterial Enumeration
S pneumoniae ATCC 6301 stocks were stored at −80°C in brain heart infusion broth containing 10% glycerol until use. Bacteria were cultured on trypticase soy agar with 5% sheep blood agar plates and incubated overnight at 37°C and 5% carbon dioxide. The bacteria were collected by washing the plates twice with sterile PBS and diluted to an optical density at 600 nm for infection. The CFU concentration in the suspension was determined retrospectively by serial dilution and plating on trypticase soy agar with 5% sheep blood agar plates. For enumeration of bacteria in pulmonary and spleen tissue, lungs and spleens were removed and homogenized separately for 25 seconds using a tissue homogenizer. Ten-fold (1:10 to 1:1,000,000) serial dilutions were made in a 96-well plate.
Twenty microliters of each dilution were plated onto trypticase soy agar with 5% sheep blood plates in duplicates.
The plates were incubated overnight at 37˚C with 5% carbon dioxide, and CFU were counted after 18 hours.
Levofloxacin
The sensitivity of the ATCC 6301 strain of S pneumoniae to levofloxacin was confirmed in vitro using the Kirby
Bauer susceptibility test protocol (data not shown).
Dosage studies were performed to determine the optimum concentration of levofloxacin to be used in vivo.
Rats were intra nasally infected with 5×10 7 CFU and re- 
Results
Eight rats were in each group, as follows: control, sham therapy, and LPT, and euthanized at 48 hours; control, sham therapy, and LPT, and euthanized at 72 hours; and control, sham therapy, and LPT, and euthanized at 96
hours. In addition, each of the groups by euthanization time received either PBS or levofloxacin before euthanization. Therefore, a total of 144 rats were used in the present study. Data are presented as mean (SD) unless otherwise indicated.
LPT Protects Against Bacterial
Pneumonia in a Dose-Dependent Manner
Three applications of LPT significantly reduced the concentration of pulmonary bacteria compared with control Experimental protocol. On day 0, rats were intranasally infected with 5×10 7 Streptococcus pneumoniae colony-forming units (CFU) and randomly assigned into control (n=8), sham therapy (n=8), or lymphatic pump treatment (LPT) (n=8) groups. At 24, 48, and 72 hours after infection, rats received control, sham therapy, or LPT followed by subcutaneous injection of 40 mg/kg of levofloxacin or sterile phosphatebuffered saline (PBS). S pneumoniae CFU were enumerated at 48, 72, and 96 hours after infection. a LPT or sham therapy was administered at 24 and 48 hours after infection, and rats whose lungs and spleens were collected at 48 hours did not receive intervention at 48 hours. b LPT or sham therapy was administered at 24, 48, and 72 hours after infection, and rats whose lungs and spleens were collected at 72 hours did not receive intervention at 72 hours.
and sham therapy (P<.05) (Figure 2) . Additionally, rats did not have any CFU in their spleens (data not shown).
LPT as an Adjunctive Therapy for Levofloxacin
Levofloxacin is a fluoroquinolone that is commonly used as a first choice for the management of CAP. 3, 22 Levofloxacin reduced S pneumoniae bacteria in a dose-dependent manner over time (Figure 3 Figure 4A . Figure 4B . of the rats in the LPT plus levofloxacin group were disease free. These results are summarized in Table 1 . shown to protect against acute lung injury in rats by abrogating the microvascular leakage of water and protein in the lungs 23 and suppressing inflammatory-mediated injuries. 24 Also, light touch may have enhanced protection against infection, although this mechanism is less clear. Importantly, LPT plus levofloxacin cleared more Abbreviations: MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; RBC, red blood cell; RDW, red blood cell distribution width; WBC, white blood cell.
Effect of LPT on Hematologic Factors
Hematologic factors were within the normal range for rats at all time points measured. The differences in levels between baseline and 24 hours after infection are summarized in Table 2 . At 48, 72, and 96 hours after infection, no statistically significant differences were found in the complete blood cell count or leukocyte differential count between any of the intervention groups ( Table 3,   Table 4 , and Table 5 ).
the uptake of protein from the interstitial space and its transport to the blood 19 ; therefore, LPT may have in- We did not identify the mechanism by which LPT reduced bacteria in the lungs, which is a limitation. It is possible that LPT may enhance the delivery of levofloxacin to the lung. In support, the pharmacodynamic pattern of levofloxacin is linked to the clinical outcome, 22 and enhancing the delivery of levofloxacin to the lung via LPT would support its use as an adjunctive therapy. Furthermore, LPT has been shown to enhance kines, and chemokines to the lung. 28 If the lung is infected, measures that enhance lymph output, such as LPT, may accelerate the immune-mediated clearance of the microbes; however, whether LPT enhances this process is unknown.
Conclusion
The combination of levofloxacin and LPT significantly reduced the concentration of pulmonary bacteria compared with LPT or levofloxacin alone (P<.05). a 5×10 7 colony-forming units of S pneumoniae. Eight rats were in each control, sham therapy, and lymphatic pump treatment (LPT) group. b Data were analyzed by an analysis of variance, followed by a Tukey post hoc test, and are presented as mean (SD).
Abbreviations: MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; PBS, phosphate-buffered saline; RBC, red blood cell; RDW, red blood cell distribution width; WBC, white blood cell.
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(continued)
LPT acts synergistically with antibiotics for the treatment of patients with pneumonia. Translational studies such as the current study are crucial to identify the mechanisms by which LPT protects against infectious disease and to support its clinical use in patients with pneumonia. Once these mechanisms are understood, LPT can be optimally applied to patients with pneumonia, which may substantially reduce morbidity, mortality, and the cost of hospitalization. 
